Carna Biosciences, Inc.

4572

JP3220550002

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 07:00:00 26/06/2024 BST			5-day change	1st Jan Change
385 ^JPY	+0.52%		+1.58%	-26.25%

05-31	Carna Biosciences, Inc. announced that it has received ¥362.07 million in funding from Athos Capital Limited	CI
05-15	Carna Biosciences, Inc. announced that it expects to receive ¥362.07 million in funding from Athos Capital Limited	CI

Carna Biosciences, Inc. announced that it has received ¥362.07 million in funding from Athos Capital Limited

May 30, 2024

On May 31, 2024, Carna Biosciences, Inc. closed the transaction.

Latest news about Carna Biosciences, Inc.

Carna Biosciences, Inc. announced that it has received ¥362.07 million in funding from Athos Capital Limited	05-30	CI
Carna Biosciences, Inc. announced that it expects to receive ¥362.07 million in funding from Athos Capital Limited	05-14	CI
Fresh Tracks Therapeutics, Inc. and Carna Biosciences, Inc. Enters into Termination of License Agreement	03-07	CI
Carna Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/05/23	CI
Carna Biosciences, Inc. announced that it has received ¥11.209315 million in funding from Cantor Fitzgerald & Co.	07/12/22	CI
Carna Biosciences, Inc. announced that it expects to receive Ã‘11.209315 million in funding from Cantor Fitzgerald & Co.	21/11/22	CI
Carna Biosciences, Inc. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2022	09/05/22	CI
Brickell Biotech Obtains Exclusive Rights to Carna Biosciences' Inhibitor Portfolio Targeting Inflammatory Diseases	02/02/22	MT
Brickell Biotech, Inc. Enters into an Exclusive License Agreement with Carna Biosciences, Inc	02/02/22	CI
Carna Biosciences, Inc. Reports Consolidated Earnings Results for the Six Months Ended June 30, 2021	05/08/21	CI
Carna Biosciences, Inc. Provides Earnings Guidance for Full Year Ending December 31, 2021	05/08/21	CI
Carna Biosciences, Inc. announced that it has received ¥14.67507 million in funding from Cantor Fitzgerald & Co.	29/07/21	CI
Carna Biosciences, Inc. announced that it expects to receive ¥14.67507 million in funding from Cantor Fitzgerald & Co.	13/07/21	CI
Carna Biosciences, Inc. Reports Consolidated and Non-Consolidated Earnings Results for the Year Ended December 31, 2020	12/02/21	CI
Carna Biosciences, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2020	12/02/21	CI
Carna Biosciences, Inc. Reports Consolidated Earnings Results for the Nine Months Ended September 30, 2020	08/11/20	CI
Carna Biosciences, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2020	08/11/20	CI
Carna Biosciences, Inc. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2020	12/05/20	CI
Carna Biosciences, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2020	12/05/20	CI
Carna Biosciences, Inc. Announces Consolidated and Non-Consolidated Earnings Results for the Year Ended December 31, 2019; Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2020	07/02/20	CI
Carna Biosciences, Inc. Provides Earnings Forecast for the Fiscal Year Ending December 31, 2019	09/01/20	CI
Open Orphan Signs Contract with Carna Bioscience	18/11/19	CI
Carna Biosciences, Inc. Reports Consolidated Earnings Results for the Nine Months Ended September 30, 2019; Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2019	07/11/19	CI
Carna Biosciences, Inc. Reports Consolidated Earnings Results for the Six Months Ended June 30, 2019; Provides Consolidated Earnings Guidance for the Year Ending December 31, 2019	12/08/19	CI
Carna Biosciences, Inc. announced that it has received ¥13.41925 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm	28/07/19	CI

Carna Biosciences, Inc. is a Japan-based company mainly engaged in the drug development support business and the drug development business. The Company operates in two business segments. The Drug Development Support segment is engaged in sales of protein kinase, development of assay, as well as provision of profiling and screening service. The Drug Development segment is engaged in the research and development of kinase inhibitors and other drugs.

Sector

Biotechnology & Medical Research

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CARNA BIOSCIENCES, INC.	-26.25%	43.28M
MODERNA, INC.	+38.36%	52.73B
LONZA GROUP AG	+39.50%	39B
IQVIA HOLDINGS INC.	-8.63%	38.52B
ALNYLAM PHARMACEUTICALS, INC.	+25.46%	30.38B
CELLTRION, INC.	-11.17%	26.39B
ICON PUBLIC LIMITED COMPANY	+11.44%	26.08B
UNITED THERAPEUTICS CORPORATION	+45.09%	14.15B
MEDPACE HOLDINGS, INC.	+32.93%	12.6B
BIO-TECHNE CORPORATION	-5.30%	11.51B

Other Biotechnology & Medical Research